BOCA RATON, Fla., June 27, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing in the ...

Mattress Liquidators has turned Entero Therapeutics white as a sheet. The creditor ordered Entero to repay its loan, prompting the biotech to lay off staff from the CEO down and race to find a way out ...

We are making substantial progress in the development and on the regulatory pathways with our lead product candidate, latiglutenase, a late-stage clinical asset for the treatment of celiac disease.

Entero Therapeutics, Inc. has announced a $2 million revolving loan agreement and significant changes to its Board of Directors, appointing three new members designated by the lender, following the ...

Entero Therapeutics to integrate applications in planned Phase 3 study of latiglutenase for celiac disease and explore additional uses of technology in clinical trial compliance BOCA RATON, Fla., Sept ...

BOCA RATON, FL / ACCESS Newswire / October 30, 2025 / Entero Therapeutics, Inc. ("Entero" or the "Company") (NASDAQ:ENTO) is pleased to announce that, as a result of the acquisition of 100% of Grid AI ...

Entero Therapeutics contests these claims and is actively exploring strategic alternatives, including raising capital, restructuring debt, or pursuing a potential merger, sale, or dissolution.

BOCA RATON, FL / ACCESS Newswire / October 14, 2025 / Entero Therapeutics (NASDAQ:ENTO) didn't tiptoe into reinvention. It jumped. The company, once known for enzymes and patient trials, is now in the ...

The MarketWatch News Department was not involved in the creation of this content. BOCA RATON, FL / ACCESS Newswire / November 19, 2025 / Entero Therapeutics, Inc. ("Entero") today announced that its ...

BOCA RATON, FL / ACCESS Newswire / November 6, 2025 / Entero Therapeutics, Inc. (NASDAQ:ENTO) (“ENTO” or the “Company”), the parent company of Grid AI, announced today the signing of a Letter of ...